ESTRO 2024 - Abstract Book

S2171

Clinical - Upper GI

ESTRO 2024

Middle third

50 (31.3%)

Lower third

85 (53.1%)

GEJ

4 (2.5%)

location of anastomosis

Cervical anastomosis

92 (57.5%)

Intrathoracic anastomosis

68 (42.5%)

Concurrent chemotherapy regimen

107 (67.9%)

Pembrolizumab+paclitaxel+carboplatin

paclitaxel+carboplatin

22 (13.8%)

Cisplatin+S-1/5-Fu

31 (19.3%)

RT modality

IMRT

76 (47.5%)

VMRT

84 (52.5%)

Conclusion:

For Chinese ESCC patients, we established an individualized nomograms based on mean GF dose combined with clinical indicators to predict AL in the early postoperative period, which could help reduce the risk of postoperative AL. When planning NCRT treatment, effect should be made to limit the mean dose of GF to 14Gy or less.

Keywords: ESCC; neoadjuvant CRT, anastomotic leakage

References: